Healthcare Industry News: chronic sinusitis
News Release - September 30, 2013
Entellus Medical & CogENT Therapeutics Announce Distribution AgreementMINNEAPOLIS--(Healthcare Sales & Marketing Network)--Entellus Medical and CogENT Therapeutics announced they have reached an exclusive distribution agreement. Entellus will distribute CogENT’s XeroGel® nasal/epistaxis pack to ENT physicians. The agreement makes Entellus Medical the sole distributor of XeroGel in the United States.
XeroGel nasal/epistaxis pack is a dissolvable co-polymer of chitosan and polyethylene glycol (PEG). Upon placement, the pack absorbs fluids in the surgical field and conforms to the treatment site in order to minimize post-surgical bleeding, prevent adhesions between mucosal surfaces, and aid in the natural healing process. In addition, XeroGel can be used for the treatment of epistaxis.
“We are excited to add XeroGel to our product portfolio,” said Brian Farley, the CEO of Entellus Medical, Inc. “As a company we are committed to improving the treatment experience for patients suffering from chronic sinusitis and believe that the XeroGel chitosan co-polymer can facilitate a better post-operative experience for sinus surgery patients. In adding XeroGel to our product offerings, Entellus now provides ENTs an ever broader array of beneficial products for their sinusitis patients.”
CogENT CEO Suresh Pai was equally enthusiastic about the new agreement. "We're excited to join forces with a capable, commercialization partner like Entellus Medical to bring XeroGel's underlying clinical benefits and value proposition to a larger audience of physicians and patients. In our experience thus far, the XeroGel nasal/epistaxis pack has demonstrated a unique ability to mitigate bleeding, retain turgidity during wound healing, and provide thorough, consistent dissolution that culminates to preserve the hard work that ENT surgeons commit to each and every one of their cases while enhancing patient comfort. We look forward to working with Entellus to drive market adoption of this new and exciting product."
Entellus will begin selling XeroGel on October 21st.
About Entellus Medical
Entellus Medical (www.EntellusMedical.com) provides complete solutions for the minimally invasive treatment of chronic and recurrent sinusitis patients and is leading the way with easy-to-use, cost-effective products for office-based balloon dilation of narrowed sinus drainage pathways. With this approach, Entellus sinus dilation products also provide significant efficiency and cost-effectiveness for sinus dilation procedures performed in operating rooms. For more information on XprESS™ Multi-Sinus Dilation Tool, FinESS™ Sinus Treatment, or PathAssist™ sinus confirmation tools visit http://www.EntellusMedical.com.
Source: Entellus Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.